Armata Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $190.47M
- P/E (TTM)
- –
- Dividend yield
- –
About Armata Pharmaceuticals
Biological Products, (No Diagnostic Substances), SIC 2836
Armata is a late clinical-stage biotechnology company that develops pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. Using proprietary host-engineered manufacturing techniques, the company produces bacteriophages designed to eliminate targeted pathogens while preserving the normal human microbiome. Its pipeline includes AP-PA02, an inhaled candidate evaluated for chronic pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis, and AP-SA02, an intravenous candidate evaluated for complicated Staphylococcus aureus bacteremia. It also evaluates AP-PA03 for acute ventilator-associated pneumonia. Its therapies serve patients suffering from severe bacterial infections.
The company conducts clinical research in the United States and maintains domestic as well as foreign material subsidiaries. Its clinical scale includes three completed Phase 2 randomized, placebo-controlled trials across multiple medical centers. The provided report does not state the location of the company's corporate headquarters or its total number of facilities.
Summary of the business section of Armata Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Armata Pharmaceuticals, Inc.
- Headquarters
- Los Angeles, CA
- Address
- 5005 Mcconnell Ave 90066
- Phone
- (310) 665-2928
- Website
- www.armatapharma.com
- Employees
- 61, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Washington
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- ARMP
- Exchange
- NYSE
- IPO date
- May 20, 1994
- Shares outstanding
- 37M, Aug 6, 2026
- Public float
- $21.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-7 reverse, Aug 14, 2019; 1-for-14 reverse, May 10, 2019; 1-for-10 reverse, Apr 25, 2017; 1-for-10 reverse, Apr 24, 2017; 1-for-50 reverse, Aug 7, 2015; 1-for-50 reverse, Aug 3, 2015; 1-for-10 reverse, May 11, 2006
- SEC CIK
- 921114
- CUSIP
- 04216R102
- ISIN
- US04216R1023
- LEI
- 549300QM1VCWH8KT0S21
- EIN
- 91-1549568
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Deborah Birx | Chief Executive Officer, Director | 198,417 |
| Pierre Kyme | Chief Business Officer | 9,461 |
| David Duane House | SVP, Finance, and PFO | – |
| Daniel B. Gilmer | Director | – |
| Jules Haimovitz | Director | – |
| Sarah J. Schlesinger | Director | – |
| Todd C. Peterson | Director | – |
| Robin Kramer | Director | – |
| Joseph M. Patti | Director | – |
| Kostas D. Odysseas | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr.Birx | $1.25M | $4.24M | $673.17K | $113 | – |
| FY2024 Dr Birx | $1.58M | $745.18K | $636.33K | $33 | – |
| FY2024 Dr.Birx | $1.84M | $1.00M | $636.33K | $33 | – |
| FY2023 Dr Birx | $1.13M | $1.42M | $316.27K | $58 | – |
| FY2023 Dr Varnum | $634.14K | $578.50K | $316.27K | $58 | – |
| FY2023 Dr.Birx | $1.13M | $1.42M | $316.27K | $58 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 18, 2026, we had 61 full-time employees.”
Corporate history
Events identified from SEC filings